Related Experiment Video
Updated: Jan 20, 2026

Assessment of Motor Balance and Coordination in Mice using the Balance Beam
Published on: March 10, 2011
[Statins and new-onset diabetes : benefit-risk balance]
1Service de diabétologie, maladies métaboliques et nutrition, Département de médecine interne, Centre hospitalier universitaire de Liège, 4000 Liège, Belgique.
Abstract:
Statins are the most commonly prescribed cholesterol-lowering drugs for cardiovascular prevention. Data from randomized clinical trials have shown an increased risk of diabetes mellitus type 2 (DT2) on statin treatment. These findings have been confirmed in genetic Mendelian randomization studies and in observational cohorts. The molecular mechanisms remain partly unknown. The risk of TD2 is higher with high doses of statins and in people with preexisting risk factors for T2D (prediabetes, metabolic syndrome). The cardiovascular benefit of statins overdrive by far the risk of diabetes and the prescription of statins in high risk cardiovascular subjects should not be questioned. Glycaemic monitoring and the adaptation of lifestyle and dietary measures are recommended for subjects at risk of T2D.
Insights
Statins, widely used for heart health, may increase the risk of developing type 2 diabetes (T2D). However, their cardiovascular benefits outweigh this risk, especially for high-risk individuals.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Statins are primary agents for cardiovascular disease prevention.
- Clinical trials and observational studies indicate an elevated risk of type 2 diabetes (T2D) associated with statin use.
- The precise molecular mechanisms underlying this association are not fully elucidated.
Purpose of the Study:
- To summarize the evidence regarding the increased risk of type 2 diabetes (T2D) in patients treated with statins.
- To discuss the factors influencing this risk and the clinical implications for patient management.
Main Methods:
- Review of randomized clinical trials.
- Analysis of genetic Mendelian randomization studies.
- Examination of observational cohort data.
Main Results:
- Consistent evidence demonstrates an increased incidence of T2D with statin therapy.
- Higher statin doses and pre-existing risk factors (e.g., metabolic syndrome, prediabetes) amplify T2D risk.
- The benefits of statins in cardiovascular prevention significantly exceed the associated diabetes risk.
Conclusions:
- Statin therapy remains crucial for cardiovascular risk reduction in high-risk populations.
- Glycemic monitoring and lifestyle modifications are recommended for individuals at increased risk of T2D while on statins.
Related Concept Videos
Balancing Redox Equations
Benefits of Self-Esteem
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Energy Balance
Equilibrium and Balance
Relative Risk

